Quarterly ResultMay 5, 2026, 06:48 AM
BioNTech Q1 Revenue €118.1M, Net Loss €531.9M; $1B Buyback, Restructuring
AI Summary
BioNTech SE reported a significant decline in Q1 2026 revenues to €118.1 million and an increased net loss of €531.9 million, primarily due to lower COVID-19 vaccine sales. Despite the weak financial performance, the company announced a share repurchase program of up to $1.0 billion and initiated a major manufacturing footprint consolidation expected to yield €500 million in annual savings by 2029, affecting approximately 1,860 positions. BioNTech also highlighted substantial progress in its oncology pipeline, with five new pivotal trials for pumitamig and six late-stage data readouts expected, while reaffirming its full-year 2026 financial guidance.
Key Highlights
- Share repurchase program of up to $1.0 billion over twelve months planned.
- Manufacturing footprint consolidation affecting approximately 1,860 positions.
- Expected recurring annual savings of €500 million by 2029 from restructuring.
- Q1 2026 revenues were €118.1 million, down from €182.8 million in Q1 2025.
- Q1 2026 net loss was €531.9 million, compared to €415.8 million net loss in Q1 2025.
- Five additional pivotal trials for pumitamig initiated during 2026.
- Reaffirmed full year 2026 financial guidance for revenues of €2,000 – €2,300 million.
- Cash, cash equivalents and security investments totaled €16.8 billion as of March 31, 2026.